Percheron Therapeutics Ltd
ASX:PER

Watchlist Manager
Percheron Therapeutics Ltd Logo
Percheron Therapeutics Ltd
ASX:PER
Watchlist
Price: 0.008 AUD 14.29%
Market Cap: 8.7m AUD

Net Margin
Percheron Therapeutics Ltd

-4 021%
Current
-5 153%
Average
4.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-4 021%
=
Net Income
-14.9m
/
Revenue
371.1k

Net Margin Across Competitors

Country Company Market Cap Net
Margin
AU
Percheron Therapeutics Ltd
ASX:PER
8.7m AUD
-4 021%
US
Eli Lilly and Co
NYSE:LLY
954.7B USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
505.3B USD
27%
CH
Roche Holding AG
SIX:ROG
253.1B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP
16%
CH
Novartis AG
SIX:NOVN
203.4B CHF
26%
US
Merck & Co Inc
NYSE:MRK
246.3B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
33%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
-126%
US
Pfizer Inc
NYSE:PFE
146.7B USD
16%
No Stocks Found

Percheron Therapeutics Ltd
Glance View

Market Cap
8.7m AUD
Industry
Pharmaceuticals

Percheron Therapeutics Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The firm is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.

PER Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-4 021%
=
Net Income
-14.9m
/
Revenue
371.1k
What is the Net Margin of Percheron Therapeutics Ltd?

Based on Percheron Therapeutics Ltd's most recent financial statements, the company has Net Margin of -4 021%.

Back to Top